When is a diagnostic method an abstract idea? Can you still patent isolated natural products? Are methods of treatment routine and conventional? What are the limits to patent eligibility when a machine learns a clinical protocol? This webinar will explore these questions, address recent case law and updates to the USPTO Guidelines, and leave you with some practice tips.

When you need a nondisclosure or confidentiality agreement (NDA) as part of potential new business deals, M&A discussions, or in relation to employee hires, do you simply plug in party names into an old template, execute, and move on? If so, you’re not alone. But we can all do better.

The webinar will focus on practical issues that shall be taken into account for intellectual property practitioners interested in filing in Brazil; analysis of the current trademark practice versus the provisions of the Madrid Protocol.

Intellectual property infringement on social media is both common, and often difficult to prevent. This is especially true for trademark infringement, which lacks something as straightforward as the DMCA. Join Tom Kulik from Scheef & Stone for a webinar on the practical considerations of reporting IP infringement to social media platforms: when it's appropriate, how to go about it, and how to maximize your success.

The speaker will discuss the U.S. Supreme Court’s recent decision in Iancu v. Brunetti, where the Court held that the federal trademark law banning registration of immoral and scandalous marks is a viewpoint-discriminatory regulation of expression that violates the First Amendment. This conclusion was not surprising given the fact that the Court held in 2017 in Matal v. Tam that a similar law denying registration to potentially disparaging marks was an unconstitutional regulation of the viewpoint of expression. While some commentators believe that Tam and Brunetti require the U.S. Patent and Trademark Office to register expression that is hateful, profane, vulgar, or otherwise offensive, trademark applicants still need to prove that their marks are distinctive and function as trademarks that identify a single source of goods or services. Thus, such marks may be refused registration on lack of distinctiveness or failure to function grounds. Moreover, the Justices suggested that Congress could draft a more narrow provision that would survive First Amendment scrutiny, such as a law banning registration of expression that is obscene, vulgar, or profane.

Have you ever considered becoming a NFL Players Association certified agent? If you've been interested in helping NFL players and prospects through contract negotiations, getting certified and passing the tests involved is your first step. Marcus Wiggins, NFLPA Certified Contract Advisor, is here to walk you through the process and give you tips on what you'll need to understand in order to properly advise players.

As Optivo, the world renowned anti-cancer drug, was developed by Tasuku Honjyo, the Nobel laureate, in 2017, R&D on antibody drugs has come to draw more attention than ever. In light of Japanese patent practice, pharmaceutical companies and research institutes face new challenges on the scope of patent protection when filing applications related to antibody drug patents. In his presentation, Dr. Iida will provide a brief outline of the patent practice related to antibody drugs and how you can prepare your specification to cover a broad scope of protection in Japan.